Scorpion Therapeutics
Ejecutivos
Ver el organigrama con sus 22 ejecutivos principales
Biografías más buscadas en Scorpion Therapeutics
Recientes movimientos de ejecutivos en Scorpion Therapeutics
- Michael Streit, Chief Medical Officer, ha dejado la empresa (noticia publicada el 5 de enero de 2024).
- Axel Hoos, Chief Executive Officer and Director, ha dejado la empresa (noticia publicada el 5 de enero de 2024).
- Mark Chao, se ha incorporado a la empresa como Chief Medical Officer (noticia publicada el 5 de enero de 2024).
Crear su alerta
para seguir los movimientos de los ejecutivos en Scorpion Therapeutics.
Biotecnología
Scorpion Therapeutics tiene 2.285 competidores entre los que se incluyen Lonza (Suiza), Eurofins (Luxemburgo) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Karius acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 3 de mayo de 2024).
- Transcarent acaba de anunciar una recaudación de fondos de 126 millones de dólares. (publicado el 2 de mayo de 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publicado el 2 de mayo de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Scorpion Therapeutics
- Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team - Scorpion Therapeutics
- Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor - Scorpion Therapeutics
- Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023 - Scorpion Therapeutics
- Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer - Scorpion Th
- Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selective PI3Kα Inhibitor for the Treatment of Breast Cancer and Other Solid Tumors - Scorpion Therapeutics
- Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer - Scorpion Therapeutics
- Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer - Scorpion Therapeutics
- Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Breast Cancer Symposium - Scorpion Therapeutics
- Scorpion Therapeutics to Present Preclinical Data for Potential Best-in-Class Mutant-Selective PI3Kα Inhibitor at San Antonio Breast Cancer Symposium - Scorpion Therapeutics
- Scorpion Therapeutics Announces Formation of World-Class Clinical Scientific Advisory Board - Scorpion Therapeutics
- View more press releases Close
Redes sociales sobre Scorpion Therapeutics
- Scorpion Therapeutics en Wikipedia, Google News y Yahoo Finance
- Scorpion Therapeutics en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Shelley Chu 
Llame a Scorpion Therapeutics al +1 212...
